Snapshot · Pfizer Inc. (PFE)

Data as of 2026-08-30T01:32:54.751Z

Fundamentals check

Market cap

$159.4B

P/E (TTM)

36.9

Gross margin

71.3%

Net margin

6.8%

ROE

4.9%

R&D / revenue

20.1%

Dividend yield

6.2%

FCF yield

6.9%

Latest dividend: $0.43/share (ex-date 2026-07-24, quarterly)

Summary

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

How it makes money

Revenue mix, latest fiscal year

• Biopharma Segment97.8%
• Segment Reporting, Reconciling Item, Corporate Nonsegment2.2%

Recent Events

• 2026-08-27T16:30:00.000Zpositive

  Pfizer FDA approves XFG-adapted COVID-19 vaccine (Adults 65+, 5-64 with condition)

  可能与 XFG 变体疫苗获批相关，恰逢疫苗产品线的积极进展，未明确因果。

  Source: businesswire.com

• 2026-08-27T03:55:28.000Zneutral

  Algert Global LLC Has $8.26 Million Stock Position in Pfizer Inc. $PFE

  可能与大型机构增持 Pfizer 有关，恰逢机构披露但不等同于股价动因。

  Source: defenseworld.net

• 2026-08-19T00:00:00.000Zpositive

  Price move: PFE rose 3.6%

  PFE 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-14T01:00:00.000Zpositive

  Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

  可能与 EMA 验证 Lyme 疫苗申请相关，恰逢市场对相关进展的积极情绪，未构成因果断言。

  Source: globenewswire.com

• 2026-08-04T00:00:00.000Zneutral

  PFE filed 10-Q

  可能与季度报告披露相关，恰逢公司更新，但不构成业绩指示的因果关系。

  Source: SEC EDGAR

Analyst view

Avg price target $29.5 from 2 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-12BuyBOURLA ALBERT(director, officer: Chairman & CEO)38,000 shares
• 2026-08-05BuyBuckley Mortimer J(director)37,632 shares
• 2026-08-05BuyBLAYLOCK RONALD E(director)39,231 shares
• 2026-08-05SellDAMICO JENNIFER B.(officer: SVP & Controller)3,278 shares
• 2026-06-09SellDAMICO JENNIFER B.(officer: SVP & Controller)2,000 shares

US Congress trading disclosures

• 2026-06-08Tommy Tuberville (AL)Sale$15,001 - $50,000

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。